Records 1-3 (of 3 Records) |
Query Trace: CYP1A2[original query] |
---|
Prognostic Value of CYP1A2 (rs2069514 and rs762551) Polymorphisms in COVID-19 Patients. Bozkurt I, et al. Balkan journal of medical genetics : BJMG 2023 0 0. (1) 35-42 |
Potential polymorphic CYP1A2 and CYP2D6-mediated pharmacokinetic interactions between risperidone or olanzapine and selected drugs intended to treat COVID-19. Rojas-Macetas Ariana, et al. Drug metabolism and bioanalysis letters 2022 0 0. |
Low risk of the TMPRSS2 inhibitor camostat mesylate and its metabolite GBPA to act as perpetrators of drug-drug interactions. Weiss Johanna, et al. Chemico-biological interactions 2021 2 0. 109428 |
Disclaimer: Articles listed in the Public Health
Knowledge Base are selected by the CDC Office of Public Health
Genomics to provide current awareness of the literature and news.
Inclusion in the update does not necessarily represent the views of
the Centers for Disease Control and Prevention nor does it imply
endorsement of the article's methods or findings. CDC and DHHS assume
no responsibility for the factual accuracy of the items presented. The
selection, omission, or content of items does not imply any
endorsement or other position taken by CDC or DHHS. Opinion, findings
and conclusions expressed by the original authors of items included in
the update, or persons quoted therein, are strictly their own and are
in no way meant to represent the opinion or views of CDC or DHHS.
References to publications, news sources, and non-CDC Websites are
provided solely for informational purposes and do not imply
endorsement by CDC or DHHS.
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 25, 2024
- Content source: